An eye drug biotech banks $118M and stocks its executive suite

Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency.

Raccontata dabiopharmadive.com